The HER2CLIMB study demonstrated significant efficacy of the combination of tucatinib, trastuzumab, and capecitabine (XH) in patients with locally advanced, unresectable, or metastatic HER2+ BC, including those with BM [40]. Here, ERBB2 is linked to breast cancer.